New Zealand’s PHARMAC Declines Funding For Roche’s Herceptin 12-Month Treatment For Early HER2 Positive Patients
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - New Zealand's Pharmaceutical Management Agency has decided to decline funding for Roche's Herceptin (trastuzumab) for 12-month treatment for HER2-positive early breast cancer treatment, the agency announced Aug. 7
You may also be interested in...
New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
PERTH, Australia - After much heated debate, New Zealand's newly elected National Party has overturned the Pharmaceutical Management Agency's decision to decline funding for 12-month treatment of Roche's Herceptin (trastuzumab) for HER2-positive early breast cancer treatment
New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
PERTH, Australia - After much heated debate, New Zealand's newly elected National Party has overturned the Pharmaceutical Management Agency's decision to decline funding for 12-month treatment of Roche's Herceptin (trastuzumab) for HER2-positive early breast cancer treatment
Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
Pharmaxis Completes Long-Term Safety Study Of Bronchitol